Trevena Inc. (Nasdaq: TRVN) reported disappointing results from Phase 2b BLAST-AHF study of TRV027 to treat acute heart failure. Shares of the biopharmaceutical lost 50 cents to close at $6.32.
Trevena's TRV027 fails Phase 2b study
May 16, 2016 at 17:16 PM EDT
